Skip to main content
LIFECOME BIOCHEMISTRY CO., LTD. logo

LIFECOME BIOCHEMISTRY CO., LTD. — Investor Relations & Filings

Ticker · 002868 ISIN · CNE100002QH2 LEI · 65560089EP03NANEN790 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,742 across all filing types
Latest filing 2024-07-22 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002868

About LIFECOME BIOCHEMISTRY CO., LTD.

https://www.pclifecome.com

Lifecome Biochemistry Co., Ltd. focuses on the research, development, and large-scale production of fermentation-based veterinary pharmaceuticals and feed additives. The company’s core product portfolio includes Bacitracin Zinc, Bacitracin Methylene Disalicylate (BMD), and Colistin Sulfate, available in both active pharmaceutical ingredient (API) and premix forms. These biochemical products are primarily utilized in the livestock and poultry sectors to manage enteric health and improve feed efficiency. The organization operates advanced fermentation and purification facilities, maintaining compliance with international Good Manufacturing Practices (GMP) and various global regulatory standards. By leveraging specialized biotechnological processes, the company provides high-purity solutions aimed at enhancing animal nutrition and disease prevention across international markets.

Recent filings

Filing Released Lang Actions
关于公司以简易程序向特定对象发行股票摊薄即期回报的风险提示及填补回报措施和相关主体承诺的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement by a company regarding a specific issuance of shares to particular investors using a simplified procedure. It discusses the dilution of immediate returns, risk warnings, financial impact analysis, necessity and rationality of the fundraising, related business connections, and specific measures to compensate for the dilution of immediate returns. It also includes commitments from directors, senior management, and controlling shareholders about the implementation of these measures. The document references regulatory guidelines and laws related to capital market investor protection and fundraising. It is not a full financial report like an annual or interim report, nor is it a simple announcement of a report publication. It is a detailed capital/financing update about a specific share issuance and related risk and mitigation measures. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2024-07-22 Chinese
绿康生化股份有限公司2024年度以简易程序向特定对象发行股票方案论证分析报告
Capital/Financing Update Classification · 95% confidence The document is titled "2024年度以简易程序向特定对象发行股票方案论证分析报告" which translates to "2024 Annual Report on the Simplified Procedure for Private Placement of Shares to Specific Objects." The content extensively discusses the company's plan to issue new shares to specific investors, the background and purpose of the issuance, legal compliance, pricing, use of proceeds, and impact on financial metrics. It includes detailed analysis of the issuance method, pricing principles, regulatory compliance, and the rationale for the capital raising. This is clearly an in-depth report related to a capital raising activity through a private placement of shares. It is not a brief announcement or a proxy statement, nor is it a general regulatory filing or an earnings release. The document length (15,000 characters) and detailed content confirm it is a substantive report. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2024-07-22 Chinese
未来三年股东回报规划（2024-2026）
Notice of Dividend Amount Classification · 95% confidence The document is a detailed plan outlining the company's shareholder return policy for the years 2024-2026, including dividend distribution methods, decision procedures, and adjustment mechanisms. It references regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange, and it is issued by the company's board of directors. The document is not a financial report, earnings release, or regulatory filing but rather a formal policy statement regarding dividends and shareholder returns. It is not a short announcement or a certification but a substantive policy document. Therefore, it fits best under the category of Notice of Dividend Amount (DIV), as it details dividend distribution plans and policies for shareholders over a multi-year period.
2024-07-22 Chinese
绿康生化股份有限公司2024年度以简易程序向特定对象发行股票募集资金使用的可行性分析报告
Capital/Financing Update Classification · 95% confidence The document is a detailed feasibility analysis report for a private placement of shares to specific investors, focusing on the use of raised funds for projects and working capital. It includes investment plans, project descriptions, market analysis, policy background, financial impact, and strategic rationale. The content centers on capital raising and the use of proceeds, which aligns with a Capital/Financing Update. There are no indications that this is an annual report, earnings release, or other report types. The document length is substantial and contains substantive financial and strategic information about the capital raise. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2024-07-22 Chinese
第五届董事会第三次（临时）会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the company's fifth board of directors' third (extraordinary) meeting. It includes approvals related to a simplified procedure for issuing shares to specific investors, the issuance plan, pricing, quantity, lock-up period, use of proceeds, risk warnings, and shareholder return plans. The document also mentions that some detailed reports and plans are disclosed separately on a public information website. The content focuses on board decisions and approvals regarding capital raising and share issuance, not the actual issuance or financial results. This fits the category of a Board/Management Information announcement, as it reports on board meeting resolutions and management decisions rather than financial reports or regulatory filings. The document length is over 6000 characters and contains substantive content about board resolutions, not just a brief announcement or certification. Therefore, the appropriate classification is MANG (Board/Management Information).
2024-07-22 Chinese
关于最近五年未被证券监管部门和证券交易所采取监管措施或处罚的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement from a company stating that it has not been subject to regulatory measures or penalties in the past five years. It is related to regulatory compliance and disclosure but does not contain financial data, detailed reports, or meeting materials. The length is only 463 characters, indicating it is a brief announcement rather than a full report. It does not fit into categories like Annual Report, Interim Report, or Audit Report. It is best classified as a Regulatory Filing (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2024-07-22 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.